journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/27919884/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3
#1
F Cardoso, A Costa, E Senkus, M Aapro, F André, C H Barrios, J Bergh, G Bhattacharyya, L Biganzoli, M J Cardoso, L Carey, D Corneliussen-James, G Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, A Gennari, N Harbeck, C Hudis, B Kaufman, I Krop, M Mayer, H Meijer, S Mertz, S Ohno, O Pagani, E Papadopoulos, F Peccatori, F Pernault-Llorca, M J Piccart, J Y Pierga, H Rugo, L Shockney, G Sledge, S Swain, C Thomssen, A Tutt, D Vorobiof, B Xu, L Norton, E Winer
No abstract text is available yet for this article.
December 5, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864221/cyclin-d-mediates-tolerance-of-genome-doubling-in-cancers-with-functional-p53
#2
A Crockford, L P Zalmas, E Grönroos, S M Dewhurst, N McGranahan, M E Cuomo, V Encheva, A P Snijders, J Begum, S Purewal, J Cerveira, H Patel, M J Renshaw, C Swanton
BACKGROUND: Aneuploidy and chromosomal instability (CIN) are common features of human malignancy that fuel genetic heterogeneity. Although tolerance to tetraploidisation, an intermediate state that further exacerbates CIN, is frequently mediated by TP53 dysfunction, we find that some genome-doubled tumours retain wild-type TP53 We sought to understand how tetraploid cells with a functional p53/p21-axis tolerate genome-doubling events. METHODS: We performed quantitative proteomics in a diploid/tetraploid pair within a system of multiple independently-derived TP53 wild-type tetraploid clones arising spontaneously from a diploid progenitor...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864220/estimating-12-weeks-death-probability-in-patients-with-refractory-metastatic-colorectal-cancer-the-colon-life-nomogram
#3
F Pietrantonio, R Miceli, L Rimassa, S Lonardi, G Aprile, A Mennitto, F Marmorino, S Bozzarelli, L Antonuzzo, E Tamburini, F Morano, D Rossini, F Battaglin, M Baretti, R Berenato, V Formica, S Mosconi, F Petrelli, M Ghidini, F Loupakis, D Spada, S Cinieri, G Beretta, A Falcone, F de Braud, C Cremolini
BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864219/neoadjuvant-chemotherapy-nact-increases-immune-infiltration-and-programmed-death-ligand-1-pd-l1-expression-in-epithelial-ovarian-cancer-eoc
#4
S J L Mesnage, A Auguste, C Genestie, A Dunant, E Pain, F Drusch, S Gouy, P Morice, E Bentivegna, C Lhomme, P Pautier, J Michels, A Le Formal, B Cheaib, J Adam, A F Leary
BACKGROUND: Lymphocytic infiltration at diagnosis is prognostic in EOC, however the impact of NACT on tumour infiltrating lymphocytes (TILs) or PD-L1 expression remains poorly described. PATIENTS AND METHODS: Patients with EOC and sequential samples (pre-NACT, post-NACT or relapse) were retrospectively identified. TILs were evaluated on whole sections; stromal TILs (sTILs) scored as percentage of stromal area with high sTILs defined as ≥50%; intra-epithelial TILs (ieTILs) scored semi-quantitatively (0-3) with high ieTILs ≥2...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864218/second-primary-malignancies-in-multiple-myeloma-an-overview-and-imwg-consensus
#5
REVIEW
P Musto, K C Anderson, M Attal, P G Richardson, A Badros, J Hou, R Comenzo, J Du, B G M Durie, J San Miguel, H Einsele, W M Chen, L Garderet, G Pietrantuono, J Hillengass, R A Kyle, P Moreau, J J Lahuerta, O Landgren, H Ludwig, A Larocca, A Mahindra, M Cavo, A Mazumder, P L McCarthy, A Nouel, S V Rajkumar, A Reiman, E R Serra, O Sezer, E Terpos, I Turesson, S Usmani, B M Weiss, A Palumbo
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864217/risk-of-second-malignant-neoplasms-in-women-and-girls-with-germ-cell-tumors
#6
Z Liao, M C Rodrigues, J N Poynter, J F Amatruda, C Rodriguez-Galindo, A L Frazier
Background While an elevated risk of second malignant neoplasms (SMNs) has been observed in men treated for germ cell tumors (GCTs), risk of SMNs have not been quantified in adult women nor in girls treated for GCTs.Patients and Methods One-year survivors of primary GCTs diagnosed between January 1980 and December 2012 were identified from Surveillance, Epidemiology, and End Results registries (SEER 9). Risk of SMNs were calculated using SEER*Stat.Results Among 1,507 patients, a total of 47 SMNs were identified...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864216/resistance-to-anticancer-immunity-in-cancer-patients-potential-strategies-to-reverse-resistance
#7
REVIEW
B Bonavida, S Chouaib
In the 1990's the application of immunotherapy approaches to target cancer cells resulted in significant clinical responses in patients with advanced malignancies who were refractory to conventional therapies. While early immunotherapeutics were focused on T cell-mediated cytotoxic activity, subsequent efforts were centered on targeted antibody-mediated anticancer therapy. The initial success with antibody therapy encouraged further studies and, consequently, there are now more than 25 FDA-approved antibodies directed against a range of targets...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864215/atrophic-exocrine-pancreatic-insufficiency-associated-with-anti-pd1-therapy
#8
G Long, A Hoadley, N Sandanayake
No abstract text is available yet for this article.
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864214/vasculitic-neuropathy-induced-by-pembrolizumab
#9
F Aya, V Ruiz-Esquide, M Viladot, C Font, S Prieto-González, A Prat, A Arance
No abstract text is available yet for this article.
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27836886/dietary-acrylamide-and-the-risk-of-pancreatic-cancer-in-the-international-pancreatic-cancer-case-control-consortium-panc4
#10
C Pelucchi, V Rosato, P M Bracci, D Li, R E Neale, E Lucenteforte, D Serraino, K E Anderson, E Fontham, E A Holly, M M Hassan, J Polesel, C Bosetti, L Strayer, J Su, P Boffetta, E J Duell, C La Vecchia
BACKGROUND: Occupational exposure to acrylamide was associated with excess mortality from pancreatic cancer, though in the absence of dose-risk relationship. Few epidemiological studies have examined the association between acrylamide from diet and pancreatic cancer risk. PATIENTS AND METHODS: We considered this issue in a combined set of 1975 cases of pancreatic cancer and 4239 controls enrolled in six studies of the Pancreatic Cancer Case-Control Consortium (PanC4)...
November 10, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27836885/sunitinib-in-pancreatic-neuroendocrine-tumors-updated-progression-free-survival-and-final-overall-survival-from-a-phase-iii-randomized-study
#11
S Faivre, P Niccoli, D Castellano, J W Valle, P Hammel, J-L Raoul, A Vinik, E Van Cutsem, Y-J Bang, S-H Lee, I Borbath, C Lombard-Bohas, P Metrakos, D Smith, J-S Chen, P Ruszniewski, J-F Seitz, S Patyna, D R Lu, K J Ishak, E Raymond
BACKGROUND: In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib...
November 10, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27836884/should-rectal-cancer-located-10-15cm-from-the-anal-verge-be-defined-as-colon-cancer
#12
M Swets, A J Breugom, H Gelderblom, C J H van de Velde
No abstract text is available yet for this article.
November 10, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831509/reply-to-is-the-pursuit-of-a-higher-impact-factor-fully-justified
#13
J-C Soria
No abstract text is available yet for this article.
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831508/letter-to-the-editor
#14
Suzette Delaloge, David Peérol, Mathieu Robain, Christian Cailliot
No abstract text is available yet for this article.
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831507/surgical-management-of-complex-residual-masses-following-systemic-chemotherapy-for-metastatic-testicular-germ-cell-tumours
#15
A Heidenreich, F Haidl, P Paffenholz, Ch Pape, U Neumann, D Pfister
BACKGROUND: Postchemotherapy retroperitoneal lymphadenectomy (PC-RPLND) represents the treatment of choice in patients with residual masses following chemotherapy for metastatic germ cell tumors. Involvement of major retroperitoneal vessels or thoracic/lumbar spine is rare and challenging but needs complete resection for curative intent. We report on our experience in the management of such complex cases. PATIENTS AND METHODS: A total of 185 patients underwent PC-RPLND and we identified 25 (13...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831506/causes-of-death-among-cancer-patients
#16
N G Zaorsky, T M Churilla, B L Egleston, S G Fisher, J A Ridge, E M Horwitz, Je Meyer Md
BACKGROUND: The purpose of our study was to characterize the causes of death among cancer patients as a function of objectives: (I) calendar year, (II) patient age, and (III) time after diagnosis. PATIENTS AND METHODS: US death certificate data in SEER Stat 8.2.1 were used to categorize cancer patient death as being due to index-cancer, non-index-cancer, and non-cancer cause from 1973 to 2012. In addition, data were characterized with standardized mortality ratios (SMRs), which provide the relative risk of death compared to all persons...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831505/research-needs-in-breast-cancer
#17
REVIEW
F Cardoso, N Harbeck, C H Barrios, J Bergh, J Cortés, N El Saghir, P A Francis, C A Hudis, S Ohno, A H Partridge, G W Sledge, I E Smith, K A Gelmon
New research questions emerge as medical needs continue to evolve and as we improve our understanding of cancer biology and treatment of malignancies. Although significant advances have been made in some areas of breast cancer research resulting in improvements in therapies and outcomes over the last few decades, other areas have not benefited to the same degree and we continue to have many gaps in our knowledge. This article summarizes the 12 short and medium-term clinical research needs in breast cancer deemed as priorities in 2016 by a panel of experts, in an attempt to focus and accelerate future research in the most needed areas: 1) de-escalate breast cancer therapies in early breast cancer without sacrificing outcomes; 2) explore optimal adjuvant treatment durations; 3) develop better tools and strategies to identify patients with genetic predisposition; 4) improve care in young patients with breast cancer; 5) develop tools to speed up drug development in biomarker-defined populations; 6) identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies; 7) evaluate the efficacy of local-regional treatments for metastatic disease; 8) better define the optimal sequence of treatments in the metastatic setting; 9) evaluate the clinical impact of intra-patient heterogeneity (intra-tumor, inter-tumor and inter-lesion heterogeneity); 10) better understand the biology and identify new targets in triple-negative breast cancer; 11) better understand immune surveillance in breast cancer and further develop immunotherapies; and 12) increase survivorship research efforts including supportive care and quality of life...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831504/industry-corner-perspectives-and-controversies
#18
C-N Gann, N Morsli, R Kaiser
The pathway for accessing new therapies can be lengthy. Once a drug is approved, reimbursement must be agreed at a national, regional and, sometimes, local level, before becoming accessible to the majority of patients, resulting in staggered patient access to a new therapy. Health technology assessments (HTAs) have become important to determine patients' access to innovative oncology medicines. In addition to HTAs, there are several initiatives that aim to provide harmonised standards for evaluating the value of cancer treatment regimens...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831503/a-randomized-trial-of-tlr-2-agonist-cadi-05-targeting-desmocollin-3-for-advanced-non-small-cell-lung-cancer
#19
C P Belani, B Chakraborty, R Modi, B Khamar
BACKGROUND: Randomised controlled trial to evaluate synergy between taxane plus platinum chemotherapy and CADI-05, a TLR-2 agonist targeting desmocollin-3 as a first line therapy in advanced Non Small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to Cisplatin-Paclitaxel (Chemotherapy group, N=112) or Cisplatin-Paclitaxel plus CADI-05 (Chemoimmunotherapy group, N=109). CADI-05 was administered a week prior to chemotherapy and on day 8 and 15 of each cycle and every month subsequently for 12 months or disease progression...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27831502/dual-her2-blockade-with-pertuzumab-and-trastuzumab-in-her2-positive-early-breast-cancer-a-subanalysis-of-data-from-the-randomized-phase-iii-geparsepto-trial
#20
S Loibl, C Jackisch, A Schneeweiss, S Schmatloch, B Aktas, C Denkert, H Wiebringhaus, S Kümmel, M Warm, S Paepke, M Just, C Hanusch, J Hackmann, J-U Blohmer, M Clemens, S Dan Costa, B Gerber, K Engels, V Nekljudova, G von Minckwitz, M Untch
BACKGROUND: The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n=396) in comparison to the HER2- cohort...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"